Ingredient in common cough medicine may aid diabetes treatment
the ONA take:
An ingredient found in common cough medicine may be able to aid in the treatment of patients with type 2 diabetes, according to a study published in Nature Medicine.
Researchers examined the effects of dextromethorphan, an active ingredient in cough suppressants, in order to build on prior research which showed that it had potential impact on receptor cells in the pancreas. Initially they hypothesized that the compound would actually worsen insulin production.
Instead, the team found that the ingredient caused the receptor cells to boost insulin production in the pancreas.
They tested the effect with a single-dose trial in 20 male patients with diabetes and found that the men “showed enhanced serum insulin concentrations and glucose tolerance.”
Findings, however, are still preliminary, and the researchers advise against diabetics self-medicating with cough medicine. Future testing was encouraged by the team.
An ingredient found in common cough medicine may be able to aid in the treatment of patients with type 2 diabetes.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Mammograms (Fact Sheet)
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|